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Abstract
Chronic diseases are often described by stages of severity. Clinical decisions about what to do are influenced
by the stage, whether a patient is progressing, and the rate of progression. For chronic kidney disease (CKD),
relatively little is known about the transition rates between stages. To address this, we used electronic health
records (EHR) data on a large primary care population, which should have the advantage of having both
sufficient follow-up time and sample size to reliably estimate transition rates for CKD. However, EHR data
have some features that threaten the validity of any analysis. In particular, the timing and frequency of
labratory values and clinical measurements are not determined a priori by research investigators, but rather,
depend on many factors, including the current health of the patient. We developed an approach for
estimatating CKD stage transition rates using hidden Markov models (HMMs), when the level of information
and observation time vary among individuals. To estimate the HMMs in a computationally manageable way,
we used a “discretization” method to transform daily data into intervals of 30 days, 90 days, or 180 days. We
assessed the accuracy and computation time of this method via simulation studies. We also used simulations
to study the effect of informative observation times on the estimated transition rates. Our simulation results
showed good performance of the method, even when missing data are non-ignorable. We applied the methods
to EHR data from over 60,000 primary care patients who have chronic kidney disease (stage 2 and above). We
estimated transition rates between six underlying disease states. The results were similar for men and women.
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Introduction
The severity of many chronic diseases, including cancer and 
chronic kidney disease (CKD), are characterized, at least in part, 
by stages. The stage of disease and rate of progression or regression 
are important to deciding whether to treat, how to treat, and how 
often to monitor a patient. Moreover, knowledge about transition 
rates between stages helps patients understand what to expect and 
policymakers what to plan.
One approach for analyzing disease stage data is hidden Markov 
models (HMMs) (MacDonald and Zucchini 1997, 2009). Unlike 
ordinary Markov models, HMMs account for the fact that some-
times the observed disease stages are different from the underlying 
disease stages as a result of measurement error. Recently, research-
ers have used continuous-time HMMs to analyze data in a variety 
of clinical areas, such as hepatocellular cancer (Kay 1986), HIV 
progression (Satten and Longini 1996), and aortic aneurysms (Jack-
son 2003). However, a continuous-time model is computationally 
costly, and may be infeasible if the sample size is large, which 
is typically the case with electronic health records (EHR) data. 
Further, for many studies there would be no benefit to having finer 
information about the timing of a measurement than the calendar 
date. Discrete-time HMMs are a useful alternative, and have been 
developed and applied to a variety of health problems (Shirley et al. 
2010; Rabiner 1986; Jackson and Sharples 2002; Scott 1999; Scott 
2002; Scott et al. 2005; Gentleman et al. 1994; Bureau et al. 2000). 
While discrete-time HMMs have many desirable features, the 
estimation of transition rates typically requires large observational 
studies with long follow-up times as transitioning usually occurs 
over years. The resources required for such studies are often costly 
and time prohibitive. Use of longitudinal EHRs data from large 
primary care practices offers an alternative means of assembling 
longitudinal health experience of a population. Such data have the 
advantage of having both sufficient follow-up time and sample size 
to reliably and accurately estimate these rare transition rates. 
In this paper we address challenges with using estimated glomer-
ular filtration rate (eGFR) to study transition rates for chronic 
kidney disease (CKD). While large populations with years of lon-
gitudinal EHR data seem well suited for estimating CKD transition 
rates, two problems arise. First, unlike planned observational stud-
ies, digital patient records vary substantially in when (e.g., a patient 
seeks care for a problem) and why (i.e., a physician decides what to 
measure) a measurement is obtained, including measuring in rela-
tion to the severity of the underlying disease state. While eGFR is 
routinely measured on patients, the reason for measurement is also 
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related to health status. Relatedly, measurement frequency varies 
substantially among patients and is often sporadic, leading to infer-
ential challenges for handling these diverse types of missing data. 
Second, the size of the data set makes it challenging to fit complex 
models that involve computationally expensive optimization.
The objectives of this paper are to test methods for HMM that can 
address the challenges of estimating transition rates from large 
EHR data sets with irregular and potentially informative observa-
tion times. We deal with the size of the data and the irregularity of 
the observation times by developing a discretization method that 
transforms daily data (with a high degree of missingness) to data 
from wider time ranges. We use simulation studies to explore the 
impact of discretization assumptions on bias and variability, as well 
as on computing time. 
In order to ensure that the simulation results are particularly rele-
vant to CKD, we first conducted a preliminary analysis of the CKD 
data. In the simulation studies, we simulated data from models 
whose parameters were similar to those from the CKD analysis. To 
address concerns about potentially informative observation times 
(i.e., the decision to obtain or not obtain eGFR on a given date 
might depend on the observed health state), we conduct simulation 
studies where we apply our method to simulated data that have in-
formative observation times. We find that the informative observa-
tion times do not have significant impact on the inference. We also 
demonstrate the feasibility of using this method on large EHR data, 
and present results from the CKD data as an illustration.
The rest of the paper is organized as follows: Section 2 describes 
the CKD study. Section 3 gives a brief introduction to HMMs and 
discusses in detail the HMM we proposed to fit the CKD data. 
Section 4 describes the simulation study and provides the results. 
The results of the CKD analysis are presented in Section 5. Finally, 
Section 6 includes a discussion of the findings, their implications, 
and some of the future research interests.
Background and Data
The study was approved by the Institutional Review Boards (IRBs) 
of Geisinger Health System and the University of Pennsylvania. 
Methods on CKD stages, access to EHR data, and HMM are de-
scribed herein.
Chronic Kidney Disease
National Kidney Foundation Kidney Disease Outcome Quality 
Initiative (NKFKDOQI) classifies a patient’s CKD as being in one 
of five stages, defined by the level of the patient’s estimated glomer-
ular filtration rate (eGFR) (Levy et al. 1999): kidney impairment 
with normal kidney function (stage 1, eGFR> 90), kidney impair-
ment with mildly decreased kidney function (stage 2, eGFR 60-89), 
moderately decreased kidney function (stage 3, eGFR 44-59), se-
verely decreased kidney function (stage 4, eGFR 15-29) and kidney 
failure (stage 5, eGFR< 15). Many patients who have CKD progress 
through these stages.
Data Description
All data for this study was derived from the Geisinger Health System 
(GHS), an integrated delivery system offering health care services to 
residents of 31 of Pennsylvania’s 67 counties with a significant presence 
in central and northeastern Pennsylvania. GHS includes the Geising-
er Health Plan (GHP), an insurance plan, and the Geisinger Clinic 
(GC)—two major independent business entities with overlapping 
populations—as well as a host of other provider facilities (e.g., hospitals, 
addiction centers, etc.). GC primary care physicians manage approxi-
mately 400,000 patients annually. Adult (i.e., 18+ years of age) primary 
care patients were the source population for this study. These patients 
were similar to those in the region and were predominantly caucasian.
For this study, a database was created from EHR data of GC primary 
care patients that encompassed whether or not they were insured by 
GHP. All health information was integrated, including laboratory 
orders and results, medication orders, and inpatient (since 2007) and 
outpatient encounters. Longitudinal data were available for the period 
from July 30th, 2003 to Dec. 31st, 2009. Patients’ disease stages were 
evaluated according to eGFR values. Data were obtained from the Na-
tional Kidney Registry and the Social Security Death Index, in order to 
determine dates at which any patients had dialysis, a kidney transplant, 
or died. Demographic variables routinely collected as part of patient 
care, such as age and gender, were also available.
Subjects were included in the study if they were between the ages of 30 
and 75 years old, had Stage 2 or higher CKD at the time of their first 
eGFR, and had at least two valid values of disease stage (eGFRs, dialy-
sis, kidney transplant, death). A total of 66,633 patients satisfied these 
criteria. Table 1 shows the baseline demographic information of our 
sample, where we define baseline as the date of first observed eGFR. 
The percentages of female and male were similar for patients who start-
ed with stage two CKD, but there were significantly more females than 
males who started with later stages of CKD. The mean age was 55 years 
old in both the male and female patients. The younger median age for 
stages 4 and 5 indicates the selection inherent to the prevalent sample 
because older patients are more common in more severe CKD stages 
and the risk of death among older patients is higher. There were 2,610 
patients recorded with either dialysis, kidney transplant, or death as the 
outcome at the end of study. 
eGFR was obtained as part of a routine laboratory protocol and to 
monitor patients with CKD. As such, the time interval between lab 
measurements varied substantially among patients. The average 
number of eGFRs was four with a range of visits from 2 to 155 and 
a median number of 144 days between measurements with a range 
of 1 day to 2,169 days. Measurement of eGFR was more frequent 
for patients with more advanced stages of CKD increasing from 
a median of 144 days between measures for patients with Stage 2 
CKD to 91 days for Stage 3 CKD patients, 22 days for Stage 4 CKD 
patients, and 11 days for stage 5 CKD patients. Figure 1 shows the 
distribution, by gender, of the number of days until the next visit 
for different CKD stages. Overall, the distributions are similar 
between men and women except for CKD stage 5 where men have 
more frequent visits than women. It should be noted that the data 
include both prevalent and incident cases.
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Statistical Model and Methodology
Introduction to Hidden Markov Model
A hidden Markov model (HMM) consists of two components: an 
observable component and an unobservable or “hidden” component. 
The hidden component behaves as a Markov process, which is a 
stochastic process with the memoryless property (MacDonald and 
Zucchini 2009). The property states that conditional on the present 
state of the process, its future and past are independent. Let ht be the 
hidden state at time t, where t = 1, ...T , and assume each state can take 
a discrete value from the state space S, ht = 1, ...S. For example, in the 
CKD example, ht would represent the true (unobserved) disease state 
at time t, where the possible disease states are 1, 2, . . ., S. This “hidden” 
or ”latent” variable h, is assumed to follow the Markov process 
expressed below:
Pr(ht+1 = s|ht = r, ht?1, ..., h1) = Pr(ht+1 = s|ht = r)
where r, s ? S. The above equation depicts a discrete-time HMM 
because the transition from State r at time t to State s at time t + 
1 happens in an equally spaced time interval, denoted by a time 
increase of 1 unit. A time-homogeneous discrete-time HMM 
?????? the transition probability from state r to s is the same 
regardless of the time t:
Pr(ht+1 = s|ht = r) = Pr(ht+k+1 = s|ht+k = r)
Of course, because h is unobserved, estimation of transition rates 
will need to rely on linking observed variables to the unobserved 
variable. Let yt denote the observed state at time t, t = 1, ...T , and 
take a discrete value from,1, ..., M. For example, in the CKD data 
yt would represent the observed stage of CKD (1 to 5), based on 
eGFR. This may or may not coincide with the “true” disease state, 
as eGFR is measured with error and is an imperfect marker of 
disease. The probability of observing state m given that the hidden 
state is r at time t, is expressed as Pr(yt = m|ht = r). This is called 
the “state-dependent distribution” because the distribution of the 
observed value depends on the value of the hidden state.
There are three sets of parameters in a discrete-time HMM: the 
initial state probability, π, the transition probability matrix, Γ, and 
the state-dependent probability, P. The initial state probability, π 
= (π1, ...πS ), specifies the distribution of the first hidden state, h1. 
The transition probability matrix, Γ(S) where S denote the hidden 
state space, can be used to describe the distribution of the hidden 
state at time t + 1 given the hidden state at time t.
The element, γ12, for example, is the probability of transitioning 
from State 1 at time t to State 2 at time t + 1, Pr(γt+1 = 2|γt = 1). 
The transition probability matrix requires that each row must sum 
to 1: j ?ij = 1, i = 1, ...S. Given the hidden state at time t, the ob-
served states are independent from each other and can take on a 
range of values with a probability distribution. It can be described 
using a probability matrix, P (S, M), where S denotes the hidden 
state space and M denotes the observed state space.
Table 1. Baseline demographic characteristics 
Female Male Total
Count
Stage 2-5
Stage 2
3
4
5
37,507(56%)
33,105(55%)
4,215(65%)
168(60%)
19(70%)
29,126(44%)
26,722(45%)
2,283(35%)
113(40%)
8(30%)
66,633
59,827
6,498
281
27
Median and IQR of age
All stages
Stage 2
3
4
5
55(21)
54(20)
67(13)
64(14)
62(13)
55(20)
54(19)
66(13)
62(15)
61(12)
55(20)
54(20)
66(13)
63(15)
62(13)
Figure 1. The boxplot shows the distributions, by CKD 
stages and gender, of the average number of days 
between measurements.
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The element, p12, for example, is the probability of observing State 2, 
given that the hidden state is 1 at time t, Pr(yt   = 2|ht = 1). Like the 
transition probability matrix, each row of the state-dependent proba-
bility matrix must also sum to 1:
  
M
 pij = 1, i = 1, ...S 
The HMM for the CKD Data
If we assume that transitions between disease states are observed 
only at clinical visits, then a continuous-time HMM would be 
ideal to fit the CKD data because these visits happen at irregular 
times. However, such models require converting an instantaneous 
probability matrix to a probability matrix of time t in the con-
struction of likelihood. It is computationally expensive because 
the probability matrix needs to be calculated at each time point 
for all the patients and the CKD data has many patients with 
long follow-up times. In our experience, built-in optimization 
functions in R, such as optim, have difficulty with likelihoods that 
involve latent classes and many parameters. Further, we attempt-
ed to use an existing R package for HMMs, but were unable to 
achieve convergence. If, however, we assume that transitions hap-
pen on a daily basis, then a discrete-time HMM can be used since 
transitions occur at a fixed interval length. A discrete-time HMM 
is more computationally efficient than a continuous-time HMM 
because it models a transition probability matrix rather than an 
instantaneous probability matrix. For daily transitions, ideally, 
we would like to observe the eGFR every day or on any given day. 
However, the observations of eGFR from EHRs are mostly spo-
radic. For purposes of modeling, we define all days between days 
with an observed eGFR to have a missing eGFR value. The combi-
nation of observed and missing values yields a very large data set 
that is computationally expensive to use for HMM. Moreover, the 
daily granularity of the data is far more refined than is necessary 
given the usual rate of change in eGFR. We therefore considered 
alternatives, where, rather than daily data, we explored the use 
of different interval lengths (30, 90, and 180 days). For example, 
when using a 30-day interval, we use the average of the multi-
ple observed states within one interval to determine observed 
status. If this average is not an integer, then either the ceiling or 
the floor of the average will be used depending on the value of 
the last observed state in the interval. For example, if the average 
within a particular state is 2.4 and the last observed state is 4, 
State 3 will be the value in this interval. If the last observed state 
is 1, then State 2 will be used instead. In the last interval, if State 
5 is observed along with other values, then State 5 will be used. If 
there are only missing values in the interval, then a missing value 
is assigned. We used simulation studies to explore the association 
between interval length and bias.
Once the CKD data are combined into different interval lengths, 
we use a discrete-time, time-homogeneous HMM with five 
observable states (1, 2, 3, 4, 5) to model the data. For the number 
of hidden states, we explored different possibilities, including 4, 
5 and 6 state models. For this section, we will describe the model 
with five hidden states (A, B, C, D, E). Generalization to other 
number of states is straightforward. The first four observed states 
(State 1, 2, 3, 4) correspond to CKD stage 2, 3, 4, and 5, where 
State 5 is the absorbing state (kidney transplant, dialysis or death). 
Once a patient enters the absorbing state, the patient will stay in it 
permanently. In other words, if a patient has a kidney transplant, 
was put on dialysis, or died, the patient can no longer regress or 
progress naturally. Note that the hidden states do not necessarily 
correspond to the observed states (i.e., hidden state B does not 
have to imply observed state 2), except for the absorbing state. 
The meaning of the hidden disease states are based on the state 
dependent probabilities.
The HMM follows a natural disease progression model, in which 
transitions are only allowed to be between adjacent states and to 
the absorbing state (Jackson 2007). This model says, for example, 
that a transition from State B to State D does not happen unless 
a transition from State B to State C occurred first. Below is the 
assumed transition probability matrix for our model.
We assume that, conditional on ht ? {A, B, C, D}, ht+1 has a 
multinomial distribution. The last row indicates that if the hidden 
state at time t is the absorbed state, then the probability of transi-
tioning to other states at time t + 1 is 0.
The state dependent probability matrix accounts for measure-
ment error in the observed data. Given the hidden state is j, the 
observed state expresses the error distribution, in this case, the 
distribution is multinomial.
We assume that only j or the adjacent states, j ? 1 or j + 1, can 
be ???????????????????????????????????????? ?????????????????
the number of parameters needed to be estimated, and it seems 
to represent the majority of the measurement error in the CKD 
data. The absorbing state is assumed to be observed without error. 
This means that if a patient had a transplant or died, it would be 
recorded accurately without the possibility of error.
4
eGEMs (Generating Evidence & Methods to improve patient outcomes), Vol. 1 [2013], Iss. 3, Art. 6
http://repository.edm-forum.org/egems/vol1/iss3/6
DOI: 10.13063/2327-9214.1040
eGEMs
5
Each row of the above matrix has a multinomial distribution with 
0 probability of observing State 5 if the hidden state is not State 
E. The last row shows that if the hidden state is State E, then the 
probability of observing State 5 is 1.
Lastly, the initial hidden state probability distribution, which 
assigns probabilities to the hidden state at t = 1, will also have a 
multinomial distribution and can be represented with a vector, 
π=(πA,...,πD , 0). The last element of the vector is set to 0 because 
we assumed that patients cannot enter the study if they are already 
in State E.
Methodology
Assume the hidden state, hit, where i = 1, ..., N and t = 1, ..., Ti, takes 
on a discrete value, s, from a sample space, S such that S = (A, B, C, 
D, E). The observed state, yit, can also take on a discrete value, m, 
from a sample space, O, such that, m = 1, ..., M . At time t and given 
the hidden state, hit, yit can be observed from a state-dependent 
probability distribution. The likelihood of the observed data for all 
subjects given the parameter, θ = (π, Γ, P ) is below:
It is difficult to estimate θ directly from the above likelihood be-
cause of the product of summations. Instead, the expectation-max-
imization (EM) algorithm can be used; for HMMs, a special case 
of the EM algorithm was developed by Baum and Welch (1970) 
and is called the “Baum-Welch algorithm.” The EM algorithm 
makes use of the augmented likelihood of the complete data (ob-
served data, Y , and hidden data, H ):
The EM algorithm involves iteratively computing the expected 
value of the observed likelihood given the current estimates of the 
parameters (the E-step) and then maximizing this observed likeli-
hood over the parameters (the M-step). The computational details 
of the EM algorithm, the likelihood and θ are listed in the appen-
dix. We use the nonparametric bootstrap to derive the standard 
errors (SEs). The resampling is done at the patient level.
Simulation Study
Data Generation
We conducted simulation studies to investigate the bias caused by 
different interval lengths and to investigate the effect of different 
missing data mechanisms on bias and variability. The reason for 
using intervals rather than analyzing daily data is to reduce the 
computational burden. The simulations are intended to provide 
information about the trade-off between bias, variability and com-
puting time. As seen in Table 1, there is a large amount of variabil-
ity in the frequency at which lab values are collected in EHRs. This 
is potentially a type of informative missing data. The simulation 
study is designed to provide insight into the effect that informa-
tive missingness might have on inference. Data in the simulation 
study were simulated to mimic the CKD data. We have used five 
hidden and five observed states to perform exploratory analysis on 
the CKD data. The results are used as the parameter values in the 
simulation. The simulation and all the analysis are coded in R.
First, complete daily status (i.e., no missing data) for 5,000 
subjects, each with data up to six years, were generated using the 
discrete-time, time-homogeneous HMM described in section 3.2. 
The first hidden state, hit, was generated with initial probabilities π 
= (0.80, 0.10, 0.07, 0.03, 0.0). Then, the first observed state, yit, was 
generated with state-dependent probability matrix:
.
The rest of the data were created in two steps. In the first step, the 
hidden state at time t, hit, t = 2, ..., Ti was generated using the 
transition probability matrix. The 180-day transition probability 
matrix is listed below.
The daily transition probability, which is used to generate the 
true disease status, can be derived by calculating Γ 180 . Since the 
progression of CKD at a later stage is more aggressive than that of 
an earlier stage, in the transition probability matrix, γ45 > γ34 > 
γ23 > γ12. We assumed that the regression of the disease was the 
same across all the states. In the second step, the observed state 
at time t, yit, were generated with the state-dependent probability 
matrix again. This sequence of data were terminated when either 
six years of data were created or the absorbing state, State 5, was 
reached.
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Missing Data Mechanisms. Next, we generated an indicator vari-
able for missing data. Let Wit be the indicator variable of whether 
the value at time t was missing for subject i (equal to 1 if missing 
and 0 otherwise). We assumed that the first and the last values 
will always be observed. This assumption ensures that at least one 
transition will be observed for each subject.
?????????????? ???????????? ???????????????????? ????????????
mechanism would be valid under the missing at random (MAR) 
assumption. MAR means that the missing data mechanisms 
depends only on the observed data. The missing data indicator 
variable, Wit, was generated sequentially, starting at visit 2 (since 
we assume no missing data at visit 1). In particular, we assume 
that Pr(Wit) depends only on the most recent observed value of y. 
For the second missing data mechanism, we assumed that Pr(Wit) 
depends only on yi,t?1, regardless of whether it was observed 
or not. This mechanism violates the MAR assumption because 
yi,t?1 might not be observed, hence, it is a type of missing not 
at random (MNAR). We call this mechanism MNAR1. ?????????
missing data mechanism that we considered assumes that the 
probability of missingness at time t depends only on the hid-
den state, hit at time t. This mechanism also violates the MAR 
assumption because h is never observed. We call this mechanism 
???????????????????????????????????????? ??????? ??????????
??????????????????????
??????????????????????????????????? ??????? ??????????
Missing Mechanism ?????????
MAR Pr(Wit  = 1|yij  = 1)
MNAR1 Pr(Wit  = 1|yit?1  = 1)
MNAR2 Pr(Wit  = 1|hit  = 1)
 
For each missing data mechanism, we further used three schemes 
to describe the differences in the number of days until the next 
visit. These three schemes are displayed in Table 3. Each cell gives 
the probability of being missing at each time. These probabilities 
determine how long on average a patient will wait until the next 
visit. The value in parentheses indicates the average number of 
days until the next visit. In scheme 1, the probability αk is chosen 
so that the number of missing values between two observed values 
mimics the actual CKD data. In the CKD data, individuals with 
CKD stage 2 tend to have a longer time for the next eGFR mea-
surement than individuals in CKD stage 3 and later stages. For 
patients in stage 2, the average time to the next measurement is 
169 days. This time dropped down to 93 days for patients in stage 
3, and so on. Hence, the lower the value of k, the higher the value 
of αk. In scheme 2, αk also depends on the value of k but the range 
for the number of days until the next visit (50–100 days) is shorter 
in length than the ones from scheme 1 (11–143 days). In scheme 
3, the range of the duration (2–200 days) is longer in length than 
the ones from scheme 1 (11–143 days). αk is assigned such that the 
sample size among the three schemes are similar. These schemes 
are intended to represent different realistic scenarios and are a 
good way to test the robustness of our model.
Table 3. Probability of missing data on a given day, 
in each disease state, for each of the 3 missing data 
scenarios
Scheme State 1 State 2 State 3 State 4
1
2
3
0.993 (143)
0.990 (100)
0.995 (200)
0.989 (91)
0.987 (77)
0.950 (20)
0.954 (22)
0.984 (62)
0.750 (4)
0.909 (11)
0.980 (50)
0.550 (2)
Note: The number in parentheses is the average number of days until the next observed 
value.
Finally, we used our “discretization” method to group the daily 
data into intervals of 30, 90, and 180 days.
Analysis. The convergence criteria used was less than 0.1 percent 
maximum difference between the current estimates and previous 
estimates. For each scenario and each parameter, we recorded the 
average value of the parameter estimates, the empirical standard 
deviation, and the absolute bias. In addition, the average time to 
convergence was recorded. 
Results
We report detailed results here for all the missing data mecha-
nisms in scheme 1 (the number of days till the next visit mimics 
the actual CKD data). The other two schemes had very similar 
results and are reported in the appendix. Table 4 lists the average 
computation time (seconds) used in 100 simulations for each 
interval length and the missing mechanisms. As expected, the 
convergence time decreases as the interval length increases. There 
seems to be more savings in going from the 30 day interval to the 
90 day interval, compared to going from the 90 day to the 180 day 
interval. The computational times are not much different among 
different missing mechanisms within each interval length.
Table 4. The average computation time (seconds)
Missing Mechanism 30 Day 90 Day 180 Day
MAR
MNAR1
MNAR2
9592
8602
9394
2821
4106
3790
2373
1513
2602
Tables 5–13 list the parameter estimates and empirical standard 
deviations (ESD) for the MAR, MNAR1, and MNAR2 mecha-
nisms, respectively. Figures 2–3 show a graphical comparison 
of the absolute biases of different intervals and different missing 
mechanisms for the transition- and state-dependent probability 
parameters. The results show that, in general, there is not a lot of 
bias regardless of which interval length was selected. The estimates 
from the 30-day interval tended to have the least bias and the ones 
from the 180-day interval tended have the most bias. This result 
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is not surprising since the shorter interval length means fewer data 
have been combined and more data are used for estimation. For 
example, consider the transition probability from State 4 to State 4, 
γDD. Under the MAR missing mechanism the absolute bias is 0.007 
in the 30-day interval, 0.013 in the 90-day interval, and 0.023 in the 
180-day interval. For each interval length, the absolute biases among 
the missing mechanisms are comparable. That is, we did not observe 
any pattern of biases tending to be larger for either NMAR1 or 
NMAR2, compared to MAR. We speculate in the Discussion section 
about why this might be the case.
For both the state-dependent and transition probability parameters, 
the ESD tended to increase as the interval length increased. This is 
expected since a widening interval decreases the number of data 
points. There was no difference in ESD for the initial probabilities, 
since the information for these parameters comes from the baseline 
data (not affected by interval length choice). We observed a larger 
impact of interval length on ESD than we did on bias. Thus, when 
choosing an interval length, the primary considerations should be 
the trade-off between standard errors and computational feasibility.
Table 5. Parameter estimates with MAR missing mechanism
True value ?ˆ (ESD) ?ˆ (ESD) ?ˆ (ESD)
30 Days 90 Days 180 Days
Initial Prob.
?
A
?
B
?
C
?
D
0.80
0.10
0.07
0.03
0.799 (0.007)
0.103 (0.005)
0.069 (0.004)
0.029 (0.002)
0.794 (0.006)
0.109 (0.005)
0.068 (0.004)
0.030 (0.002)
0.775 (0.006)
0.127 (0.006)
0.068 (0.004)
0.030 (0.002)
Table 6. Parameter estimates with MNAR1 missing 
mechanism
True Value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Initial Prob.
?
A
?
B
?
C
?
D
0.80
0.10
0.07
0.03
0.787 (0.006)
0.109 (0.006)
0.072 (0.003)
0.031 (0.002)
0.777 (0.007)
0.121 (0.005)
0.071 (0.003)
0.031 (0.002)
0.754 (0.007)
0.143 (0.007)
0.072 (0.003)
0.032 (0.003)
Table 7. Parameter estimates with MNAR2 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Initial Prob.
?
A
?
B
?
C
?
D
0.80
0.10
0.07
0.03
0.791 (0.006)
0.105 (0.005)
0.073 (0.004)
0.031 (0.002)
0.781 (0.006)
0.116 (0.005)
0.072 (0.004)
0.031 (0.002)
0.758 (0.006)
0.138 (0.006)
0.071 (0.004)
0.033 (0.003)
 
Table 8. Parameter estimates with MAR missing mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Transition Prob.
?
AA 
?
AB 
?
AE
0.90
0.07
0.03
0.895 (0.0003)
0.070 (0.0003)
0.031 (0.0002)
0.894 (0.0011)
0.073 (0.0010)
0.030 (0.0006)
0.895 (0.0023)
0.075 (0.0022)
0.030 (0.0010)
?
BA
?
BB
?
BC
?
BE
0.03
0.85
0.09
0.03
0.030 (0.0004)
0.840 (0.0008)
0.094 (0.0006)
0.030 (0.0003)
0.030 (0.0013)
0.835 (0.0022)
0.100 (0.0016)
0.030 (0.0009)
0.029 (0.0028)
0.834 (0.0045)
0.109 (0.0032)
0.029 (0.0017)
?
C B
?
C C 
?
C D 
?
C E
0.03
0.80
0.14
0.03
0.029 (0.0006)
0.799 (0.0012)
0.140 (0.0011)
0.033 (0.0003)
0.027 (0.0015)
0.795 (0.0034)
0.144 (0.0031)
0.034 (0.0015)
0.025 (0.0035)
0.795 (0.0071)
0.144 (0.0059)
0.035 (0.0030)
?
DC 
?
DD 
?
DE
0.03
0.75
0.22
0.029 (0.0008)
0.757 (0.0017)
0.213 (0.0015)
0.027 (0.0025)
0.763 (0.0042)
0.209 (0.0042)
0.023 (0.0051)
0.773 (0.0092)
0.203 (0.0077)
Table 9. Parameter estimates with MNAR1 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Transition 
Prob.
?
AA
?
AB
?
AE
0.90
0.07
0.03
0.891 (0.0004)
0.075 (0.0004)
0.030 (0.0002)
0.892 (0.0010)
0.076 (0.0010)
0.030 (0.0006)
0.894 (0.0019)
0.077 (0.0018)
0.029 (0.0010)
?
BA
?
BB 
?
BC 
?
BE
0.03
0.85
0.09
0.03
0.031 (0.0003)
0.840 (0.0006)
0.092 (0.0005)
0.030 (0.0003)
0.032 (0.0011)
0.838 (0.0020)
0.096 (0.0016)
0.029 (0.0009)
0.032 (0.0025)
0.838 (0.0043)
0.102 (0.0031)
0.029 (0.0017)
?
C B 
?
C C 
?
C D 
?
C E
0.03
0.80
0.14
0.03
0.031 (0.0005)
0.803 (0.0011)
0.135 (0.0010)
0.031 (0.0003)
0.031 (0.0016)
0.798 (0.0036)
0.139 (0.0029)
0.032 (0.0011)
0.030 (0.0033)
0.797 (0.0061)
0.140 (0.0059)
0.033 (0.0028)
?
DC 
?
DD 
?
DE
0.03
0.75
0.22
0.031 (0.0008)
0.752 (0.0017)
0.216 (0.0014)
0.031 (0.0024)
0.758 (0.0050)
0.211 (0.0039)
0.031 (0.0059)
0.768 (0.0092)
0.202 (0.0083)
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Table 10. Parameter estimates with MNAR2 missing 
mechanism
True 
value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Transition 
Prob.
?
AA
?
AB
?
AE
0.90
0.07
0.03
0.892 (0.0003)
0.074 (0.0003)
0.030 (0.0002)
0.892 (0.0011)
0.076 (0.0010)
0.030 (0.0005)
0.894 (0.0020)
0.076 (0.0019)
0.029 (0.0010)
?
BA
?
BB 
?
BC 
?
BE
0.03
0.85
0.09
0.03
0.031 (0.0004)
0.837 (0.0007)
0.096 (0.0005)
0.029 (0.0003)
0.032 (0.0013)
0.834 (0.0023)
0.100 (0.0016)
0.029 (0.0009)
0.032 (0.0023)
0.835 (0.0044)
0.105 (0.0033)
0.028 (0.0017)
?
C B 
?
C C 
?
C D 
?
C E
0.03
0.80
0.14
0.03
0.030 (0.0005)
0.805 (0.0010)
0.133 (0.0008)
0.031 (0.0004)
0.031 (0.0014)
0.800 (0.0030)
0.137 (0.0029)
0.032 (0.0014)
0.031 (0.0037)
0.798 (0.0069)
0.139 (0.0054)
0.032 (0.0029)
?
DC 
?
DD 
?
DE
0.03
0.75
0.22
0.031 (0.0007)
0.752 (0.0016)
0.216 (0.0015)
0.031 (0.0025)
0.757 (0.0048)
0.212 (0.0042)
0.030 (0.0057)
0.768 (0.0099)
0.202 (0.0081)
 
Table 11. Parameter estimates with MAR missing 
mechanism
True 
value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
State-dep. 
Prob.
p
A1
p
A2
0.90
0.10
0.905 (0.0019)
0.095 (0.0019)
0.915 (0.0019)
0.085 (0.0019)
0.925 (0.0023)
0.075 (0.0023)
p
B1 
p
B2 
p
B3
0.10
0.80
0.10
0.104 (0.0026)
0.830 (0.0028)
0.066 (0.0019)
0.112 (0.0037)
0.849 (0.0039)
0.039 (0.0020)
0.127 (0.0053)
0.846 (0.0054)
0.027 (0.0025)
p
C2 
p
C3 
p
C 4
0.10
0.80
0.10
0.139 (0.0029)
0.800 (0.0035)
0.061 (0.0019)
0.191 (0.0052)
0.766 (0.0052)
0.043 (0.0027)
0.204 (0.0070)
0.753 (0.0071)
0.043 (0.0046)
p
D3
p
D4
0.10
0.90
0.149 (0.0032)
0.851 (0.0032)
0.172 (0.0061)
0.828 (0.0061)
0.161 (0.0097)
0.839 (0.0097)
Table 12. Parameter estimates with MNAR1 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
State-dep. 
Prob.
p
A1
p
A2
0.90
0.10
0.905 (0.0019)
0.095 (0.0019)
0.905 (0.0022)
0.095 (0.0022)
0.906 (0.0024)
0.094 (0.0024)
p
B1 
p
B2 
p
B3
0.10
0.80
0.10
0.105 (0.0023)
0.806 (0.0024)
0.089 (0.0018)
0.101 (0.0026)
0.814 (0.0031)
0.085 (0.0023)
0.098 (0.0043)
0.825 (0.0043)
0.078 (0.0033)
p
C2 
p
C3 
p
C 4
0.10
0.80
0.10
0.099 (0.0021)
0.814 (0.0026)
0.087 (0.0018)
0.085 (0.0033)
0.840 (0.0039)
0.075 (0.0027)
0.074 (0.0048)
0.856 (0.0055)
0.070 (0.0050)
p
D3
p
D4
0.10
0.90
0.106 (0.0028)
0.894 (0.0028)
0.103 (0.0052)
0.897 (0.0052)
0.095 (0.0091)
0.905 (0.0091)
Table 13. Parameter estimates with MNAR2 missing 
mechanism
True 
value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
State-dep. 
Prob.
p
A1
p
A2
0.90
0.10
0.904 (0.0016)
0.096 (0.0016)
0.904 (0.0019)
0.096 (0.0019)
0.905 (0.0026)
0.095 (0.0026)
p
B1 
p
B2 
p
B3
0.10
0.80
0.10
0.104 (0.0024)
0.805 (0.0029)
0.091 (0.0022)
0.102 (0.0032)
0.810 (0.0043)
0.088 (0.0026)
0.102 (0.0041)
0.816 (0.0048)
0.082 (0.0036)
p
C2 
p
C3 
p
C 4
0.10
0.80
0.10
0.097 (0.0020)
0.812 (0.0026)
0.091 (0.0017)
0.083 (0.0034)
0.839 (0.0042)
0.078 (0.0032)
0.073 (0.0053)
0.853 (0.0058)
0.074 (0.0051)
p
D3
p
D4
0.10
0.90
0.101 (0.0025)
0.899 (0.0025)
0.100 (0.0045)
0.900 (0.0045)
0.091 (0.0072)
0.909 (0.0072)
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Application to CKD Data
We applied our proposed HMM, described in Section 3.2, to the 
CKD data, which were described in Section 2. We decided to use 
a 90-day time window, as that seemed to be a reasonable trade-off 
between computational feasibility and efficiency. We fitted separate 
models for men and women.
Number of Hidden States. Models with four, five, and six hidden 
states were fitted to the data for both male and female subgroups with 
an interval length of 90 days. We decided not to consider a seven state 
model because a model with several more latent states than observed 
states can become unstable. The Akaike information criterion (AIC) 
and the Bayesian information criterion (BIC) were calculated for all 
the models (four, five, six hidden states). The results are listed in Table 
14. The HMM with six hidden states produced much smaller AIC 
(105222.1 for male, 154025.1 for female ) and BIC (105424.7 for male, 
154227.7 for female) values than the ones with four hidden states and 
five hidden states. Since the smaller AIC or BIC indicates a better fit of 
the model, we decided to fit the data with a six hidden state (A, B, C, D, 
E, F) and five observed state (1, 2, 3, 4, 5) model.
Parameter estimates and standard errors, stratified by sex, are 
displayed in Tables 15–17.
Table 14. Comparison of HMMs
Four hidden 
states
Five hidden states Six hidden states
Men
AIC 108,895 106,224 105,222
BIC 109,009 106,378 105,424
Women
AIC 158,880 155,665 154,025
BIC 158,994 155,819 154,227
Table 15. Parameter estimates for the CKD data: 90 Day
Women Men
Estimate (SE) Estimate (SE)
Initial 
Prob.
?
A
?
B
?
C
?
D
?
E
0.799 (0.0080)
0.122 (0.0066)
0.074 (0.0025)
0.005 (0.0045)
0.000 (0.0001)
0.862 (0.0032)
0.081 (0.0033)
0.053 (0.0021)
0.004 (0.0004)
0.000 (0.0001)
Figure 2. The absolute bias of the average of 14 transition probability parameter estimates of 100 samples for each interval 
length (30, 90, 180) under MAR, MNAR1, and MNAR2 missing mechanisms. 
Note: (A,A) is the transition from State A to State A.
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State-Dependent Probabilities. We begin with the state-depen-
dent probability results, because these provide information about 
the interpretation of the hidden states. Recall that we focused on 
CKD stages 2–5 (along with the absorbing state). Thus, observed 
state y = 1 corresponds to CKD stage 2. Observed state y = 5 is 
the absorbing state (transplant, dialysis, or death). Hidden state F 
always corresponds with observed state 5. From the results in men 
(women have similar results), we see that hidden state A almost 
always corresponds with observed state 1 (stage 2 CKD). However, 
hidden state B is a mixture of observed state 1 (probability 0.58) 
and observed state 2 (probability 0.41). Thus, we could think of 
hidden state B as subjects who might be near the CKD stage 2 
and 3 boundary. Ninety-seven percent of the time, hidden state C 
corresponds with observed state 2. Thus, we could think of hidden 
state C as CKD stage 3. This finding suggests that it might be clini-
cally meaningful to divide stage 3 into stage 3a and 3b where some 
patients progress to the next stage while others do not. With hid-
den state D, state 3 has been observed 86 percent of the time and 
observed state 4 only 9 percent of the time. Thus, we could think 
of hidden state D as being subjects who are typically in CKD stage 
4. Finally, 95 percent of the time,  hidden state E corresponds with 
observed state 4. Thus, we could think of hidden state E as subjects 
who are in CKD stage 5. The SEs are very small in general, but are 
particularly small for the parameters involving hidden states A to 
C. We estimate pD3 and pD4 with a little less accuracy, which is 
not surprising due to the fact that there are far fewer subjects in 
later disease stages.
Figure 3. The absolute bias of the average of 10 state-dependent probability parameter estimates of 100 samples for 
each interval length (30, 90, 180) under MAR, MNAR1, and MNAR2 missing mechanisms. 
Note: (A,1) is observing state 1 giving the hidden state is State A.
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Table 16. Parameter estimates for the CKD data: 90 Day
Women Men
Estimate (SE) Estimate (SE)
Transition Prob.
?
AA 
?
AB 
?
AF
0.987 (0.0004)
0.011 (0.0004)
0.002 (0.0001)
0.989 (0.0004)
0.009 (0.0004)
0.002 (0.0001)
?
BA 
?
BB 
?
BC 
?
BF
0.029 (0.0015)
0.932 (0.0024)
0.036 (0.0019)
0.003 (0.0004)
0.025 (0.0025)
0.928 (0.0037)
0.038 (0.0020)
0.009 (0.0007)
?
C B 
?
C C 
?
C D 
?
C F
0.014 (0.0008)
0.973 (0.0009)
0.007 (0.0005)
0.006 (0.0004)
0.016 (0.0018)
0.962 (0.0019)
0.011 (0.0006)
0.011 (0.0007)
?
DC 
?
DD 
?
DE 
?
DF
0.031 (0.0043)
0.918 (0.0051)
0.016 (0.0019)
0.035 (0.0033)
0.029 (0.0046)
0.896 (0.0057)
0.026 (0.0036)
0.049 (0.0052)
?
ED 
?
EE 
?
EF
0.000 (0.0000)
0.839 (0.0329)
0.161 (0.0329)
0.033 (0.0152)
0.704 (0.0303)
0.263 (0.0311)
Table 17. Parameter estimates for the CKD data: 90 Day
Women Men
Estimate (SE) Estimate (SE)
State-dep. Prob.
p
A1
p
A2
0.980 (0.0010)
0.020 (0.0010)
0.986 (0.0007)
0.014 (0.0007)
p
B1
p
B2 
p
B3
0.583 (0.0194)
0.416 (0.0193)
0.001 (0.0003)
0.584 (0.0165)
0.414 (0.0164)
0.002 (0.0003)
p
C1 
p
C2 
p
C 3
0.025 (0.0026)
0.964 (0.0021)
0.011 (0.0013)
0.020 (0.0033)
0.968 (0.0031)
0.012 (0.0013)
p
D2 
p
D3 
p
D4
0.143 (0.0177)
0.847 (0.0172)
0.010 (0.0019)
0.130 (0.0192)
0.861 (0.0187)
0.009 (0.0033)
p
E3
p
E4
0.174 (0.0565)
0.826 (0.0565)
0.050 (0.0541)
0.950 (0.0541)
Initial State Probabilities. Initially, about 86 percent of men and 
80 percent of women were in hidden state A. Approximately 8 
percent were in State B and 5 percent in State C for men and 12 
percent were in State B and 7 percent in State C for women. Very 
few subjects began in hidden state D and almost none of them 
began in hidden state E. All of these parameter estimates had very 
small SEs (less than 0.005).
Transition Probabilities. The transition probabilities refer to the 
probabilities of transitioning from one hidden state to another 
within a 90-day period. In general, subjects are likely to remain in 
the same disease state over a 90-day period, with all of the same 
state probabilities at 0.70 and above. Subjects who were in State B 
were more likely to transition to State C than to State A. However, 
subjects who were in States C were more likely to transition to 
State B than to State D. Subjects who were in state D were equally 
likely to transition to state C and state E. In general, the results are 
very similar for men and women, with the exception being that the 
transition from State E to the absorbing State F is higher for men 
(0.26) than for women (0.16).
Progression probabilities (transition to the next higher state) has 
the following pattern: low for A to B, then increase for B to C, then 
decrease for C to D, but then increase for D to E and again for E to 
F. This pattern is consistent with what one might expect if there is 
a pathophysioligic channel at State C that determines if someone 
will have progressive disease.
Discussion
In this paper, we made novel use of a large EHR data set to esti-
mate disease stage transition rates. Using EHR data for this pur-
pose has many challenges, including the size of the data and the 
extreme variation (and likely informativeness) in the observation 
times. We proposed a discretization method to convert a contin-
uous-time HMM to a discrete-time HMM and studied the effect 
of different amounts of discretization in a simulation study. We 
also investigated, via simulations, what effect disease stage-depen-
dent observation times will have on the results. This is a common 
challenge with EHR data, where, typically: (1) more severe disease 
means more visits and a greater likelihood of being observed; and 
(2) the more one is observed the more the observations are condi-
tioned by a desire to monitor.
The simulation results were promising for the method of discret-
ization, in that the amount of bias was relatively small, even for 
the 180-day time window. Perhaps surprisingly, we found very 
little impact of nonignorable missing data on bias and variability. 
The missing data mechanisms that we considered depended on 
current or recent disease states. Other mechanisms might lead to 
more bias. Perhaps, for example, if the probability of missing data 
depended on the proximity to a transition, rather than the current 
disease state, there would be more bias. This is an area in need of 
further research. 
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For the CKD data, we found that of the four, five, and six hidden 
state models that we considered, the six hidden state model fits 
the data best. In the six state model, we found that all the CKD 
disease stages correspond to at least one hidden state in the model. 
One hidden state consists of subjects who are between stage 2 
and 3. This suggests that there may be a disease state that is not 
well captured by the current five stage classification system. It also 
suggested that distinguishing CKD stage 3 into a stage 3a and stage 
3b may be clinically sensible and correspond to empirical obser-
vations that some patients transition to a more severe stage while 
most patients do not. Within a 90-day period, transitions between 
hidden states were rare. The disease course, in terms of transitions 
between states, was very similar for men and women.
There were some limitations to this research. First, it should be 
noted that the population was mostly white and mostly from rural 
Pennsylvania (40 percent rural, whereas the national average is 20 
percent), and might not be representative of the general popula-
tion. Second, we used observed stages of CKD rather than eGFR 
values themselves. An alternative approach would be to relate 
eGFR values to hidden states. However, this approach is more 
computationally burdensome. Third, despite promising simulation 
results, we cannot rule out the possibility that selection bias (in 
terms of who had eGFR measured when) biased the results. It is 
also important to note that while a 90-day interval seemed to have 
good properties for CKD, a shorter window might be necessary for 
diseases that have rapid progression.
There is great potential for using EHR data to study characteris-
tics of chronic diseases, due to the large population size and long 
follow-up times. The proposed discretization method makes the 
use of HMMs applied to large data sets more practical. While the 
simulation studies were promising, it will also be important to val-
idate these results on a longitudinal CKD data set that was part of 
a research study (with planned data collection times and uniform 
standards). While transition rates themselves are important for 
understanding disease progression, the methods proposed here 
can be extended to another important area—prediction modeling. 
It is of interest to clinicians to be able to know who is likely to be a 
fast or slow progressor. Our models can be extended to allow tran-
sition rates to vary as a function of clinical predictors. The most 
direct way to do this is using stratification, like was done here for 
gender. For many predictors, the model could be extended to allow 
several latent classes for disease transition rates, with latent class 
probabilities depending on covariates.  Relatedly, the model could 
be extended to have the disease transition rates vary from person 
to person according to a random effects distribution where the 
covariates may predict the random effects (Altman, 2007; Shirley 
et al., 2010)
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Appendix
Formulas
Likelihood
Let’s assume the hidden state, hit, where i = 1, ..., N and t = 1, ..., 
Ti, takes on a discrete value, s, from a sample space, S, such that, s 
= 1, ..., S. The observed state, yit, can also take on a discrete value, 
m, from a sample space, M , such that, m = 1, ..., M . At time t and 
given the hidden state, hit, yit can be observed from a state-de-
pendent probability distribution.
From the likelihood above, we can see that given the hidden 
states, the initial state probability, the transition probability, and 
the state dependent probability have multinomial distributions 
with parameter π, γjk , and pjk . To simplify the estimation of the 
parameters, the log of this augmented likelihood is often used.
Expectation Maximization (EM) Method
To estimate the parameters, θ, an iterative algorithm called the “ex-
pected-maximization (EM) algorithm” is used. The EM algorithm 
is an iterative algorithm in which iteratively, the expected value of 
the complete data log likelihood given the current parameters is 
computed (E-step) and then this expected value is maximized over 
the parameters (M-step). The special case of the EM algorithm for 
HMMs was developed by Baum and Welch (1970). For the E-step, 
the forward-backward (FB) algorithm is used. This algorithm is 
composed of two passes: the forward and the backward (MacDon-
ald and Zucchini 1997). In the forward pass, the joint distribution 
of the observed data up to time t and the hidden state at time t is 
calculated. After all the data are observed, the backward pass will 
update the information on the hidden state from the last time point 
to the first based on all the observed data. In the forward pass, 
denoted by αt, the joint distribution of the observed data up to time 
t and the hidden state at time t is calculated as below:
After all the data are observed, the backward pass, βt, will update 
the information on the hidden state from the last time point to the 
first based on all the observed data.
The observed likelihood for each subject, i, can be calculated 
using αi in the following way:
Since there are hidden data, H, in the log likelihood, we use the 
expected value of the missing information to compute the ex-
pected value of the complete data log likelihood given the current 
parameter estimates:
The expectation of the missing data are calculated as follows. Note 
the superfix g represents the gth iteration of the parameters.
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In the M-step, θ can be estimated in closed form using the expect-
ed values derived from above.
The initial probability distribution, π, can be estimated as follows:
The transition probability, γij , where i = 1, ...S, j = 1, ..., S, can be 
estimated as follow:
The state dependent probability, pjk , where j = 1, ...S, k = 1, ..., M , 
can be estimated as follow:
The EM method does not provide the standard errors for the pa-
rameters. We have decided to estimate the standard errors using 
bootstrap with replacement.
How to Handle Missing Data
If data is missing at a particular time point, an empty transition is 
assumed to occur. This is illustrated by replacing the state depen-
dent probability, Ps,yt,with 1’s in the calculation of ?t, ?t, and E[I 
(hit = k)I (hit?1 = j)].
Simulation Results: Scheme 2
Table 18. The average computation time (seconds)
Missing Mechanism 30 Day 90 Day 180 Day
MAR
MNAR1
MNAR2
9643
14036
14941
2657
2490
2760
1568
1513
2254
Table 19. Parameter estimates with MAR missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Initial Prob.
?
A
?
B
?
C
?
D
0.80
0.10
0.07
0.03
0.799 (0.007)
0.103 (0.005)
0.069 (0.004)
0.029 (0.002)
0.794 (0.006)
0.109 (0.005)
0.068 (0.004)
0.030 (0.002)
0.775 (0.006)
0.127 (0.006)
0.068 (0.004)
0.030 (0.002)
Table 20. Parameter estimates with MAR missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Transition 
Prob.
?
AA 
?
AB 
?
AE
0.90
0.07
0.03
0.895 (0.0004)
0.071 (0.0003)
0.031 (0.0002)
0.894 (0.0011)
0.073 (0.0011)
0.031 (0.0005)
0.895 (0.0020)
0.075 (0.0017)
0.030 (0.0010)
?
BA 
?
BB 
?
BC 
?
BE
0.03
0.85
0.09
0.03
0.030 (0.0005)
0.840 (0.0007)
0.094 (0.0005)
0.029 (0.0003)
0.030 (0.0014)
0.836 (0.0021)
0.100 (0.0017)
0.029 (0.0009)
0.029 (0.0027)
0.834 (0.0046)
0.109 (0.0032)
0.029 (0.0018)
?
C B 
?
C C 
?
C D 
?
C E
0.03
0.80
0.14
0.03
0.029 (0.0006)
0.799 (0.0011)
0.139 (0.0009)
0.033 (0.0004)
0.027 (0.0016)
0.795 (0.0036)
0.144 (0.0030)
0.034 (0.0013)
0.026 (0.0037)
0.795 (0.0066)
0.145 (0.0058)
0.035 (0.0035)
?
DC 
?
DD 
?
DE
0.03
0.75
0.22
0.030 (0.0007)
0.757 (0.0017)
0.213 (0.0015)
0.028 (0.0024)
0.762 (0.0045)
0.210 (0.0041)
0.025 (0.0053)
0.772 (0.0092)
0.203 (0.0085)
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Table 21. Parameter estimates with MAR missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
State-dep. 
Prob.
p
A1
p
A2
0.90
0.10
0.905 (0.0017)
0.095 (0.0017)
0.915 (0.0018)
0.085 (0.0018)
0.925 (0.0023)
0.075 (0.0023)
p
B1 
p
B2 
p
B3
0.10
0.80
0.10
0.104 (0.0026)
0.830 (0.0030)
0.066 (0.0018)
0.112 (0.0032)
0.849 (0.0033)
0.039 (0.0018)
0.126 (0.0047)
0.846 (0.0053)
0.027 (0.0025)
p
C2 
p
C3 
p
C 4
0.10
0.80
0.10
0.139 (0.0023)
0.800 (0.0028)
0.061 (0.0017)
0.191 (0.0046)
0.766 (0.0045)
0.043 (0.0028)
0.203 (0.0078)
0.754 (0.0073)
0.043 (0.0046)
p
D3
p
D4
0.10
0.90
0.149 (0.0030)
0.851 (0.0030)
0.173 (0.0058)
0.827 (0.0058)
0.159 (0.0092)
0.841 (0.0092)
Table 22. Parameter estimates with MNAR1 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Initial Prob.
?
A
?
B
?
C
?
D
0.80
0.10
0.07
0.03
0.787 (0.006)
0.109 (0.005)
0.073 (0.003)
0.031 (0.002)
0.778 (0.007)
0.120 (0.006)
0.071 (0.004)
0.031 (0.003)
0.754 (0.006)
0.143 (0.005)
0.071 (0.004)
0.032 (0.003)
Table 23. Parameter estimates with MNAR1 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Transition 
Prob.
?
AA 
?
AB 
?
AE
0.90
0.07
0.03
0.891 (0.0004)
0.075 (0.0003)
0.030 (0.0002)
0.892 (0.0010)
0.076 (0.0009)
0.030 (0.0006)
0.895 (0.0021)
0.076 (0.0019)
0.029 (0.0011)
?
BA 
?
BB 
?
BC 
?
BE
0.03
0.85
0.09
0.03
0.031 (0.0004)
0.840 (0.0008)
0.092 (0.0006)
0.030 (0.0003)
0.032 (0.0011)
0.838 (0.0020)
0.096 (0.0015)
0.030 (0.0009)
0.031 (0.0024)
0.838 (0.0045)
0.103 (0.0034)
0.029 (0.0017)
?
C B 
?
C C 
?
C D 
?
C E
0.03
0.80
0.14
0.03
0.030 (0.0005)
0.804 (0.0011)
0.135 (0.0010)
0.031 (0.0003)
0.031 (0.0017)
0.796 (0.0033)
0.140 (0.0028)
0.033 (0.0011)
0.031 (0.0032)
0.796 (0.0063)
0.141 (0.0055)
0.033 (0.0031)
?
DC 
?
DD 
?
DE
0.03
0.75
0.22
0.031 (0.0007)
0.752 (0.0017)
0.217 (0.0016)
0.031 (0.0021)
0.756 (0.0043)
0.213 (0.0038)
0.030 (0.0049)
0.767 (0.0099)
0.203 (0.0084)
Table 24. Parameter estimates with MNAR1 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
State-dep. 
Prob.
p
A1
p
A2
0.90
0.10
0.905 (0.0017)
0.095 (0.0017)
0.905 (0.0020)
0.095 (0.0020)
0.906 (0.0024)
0.094 (0.0024)
p
B1 
p
B2 
p
B3
0.10
0.80
0.10
0.104 (0.0022)
0.806 (0.0028)
0.090 (0.0020)
0.100 (0.0026)
0.814 (0.0030)
0.086 (0.0024)
0.099 (0.0034)
0.823 (0.0035)
0.078 (0.0032)
p
C 2 
p
C 3 
p
C 4
0.10
0.80
0.10
0.099 (0.0020)
0.814 (0.0027)
0.087 (0.0018)
0.085 (0.0031)
0.840 (0.0036)
0.075 (0.0027)
0.074 (0.0047)
0.855 (0.0056)
0.071 (0.0050)
p
D3
p
D4
0.10
0.90
0.105 (0.0028)
0.895 (0.0028)
0.103 (0.0046)
0.897 (0.0046)
0.093 (0.0083)
0.907 (0.0083)
Table 25. Parameter estimates with MNAR2 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Initial Prob.
?
A
?
B
?
C
?
D
0.80
0.10
0.07
0.03
0.791 (0.006)
0.105 (0.005)
0.073 (0.004)
0.031 (0.002)
0.781 (0.006)
0.116 (0.005)
0.072 (0.004)
0.031 (0.002)
0.757 (0.006)
0.139 (0.005)
0.072 (0.004)
0.032 (0.003)
Table 26. Parameter estimates with MNAR2 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Transition 
Prob.
?
AA 
?
AB 
?
AE
0.90
0.07
0.03
0.892 (0.0004)
0.074 (0.0003)
0.030 (0.0002)
0.892 (0.0010)
0.076 (0.0009)
0.032 (0.0005)
0.894 (0.0021)
0.077 (0.0017)
0.029 (0.0011)
?
BA 
?
BB 
?
BC 
?
BE
0.03
0.85
0.09
0.03
0.032 (0.0004)
0.836 (0.0008)
0.096 (0.0005)
0.036 (0.0003)
0.032 (0.0012)
0.835 (0.0024)
0.100 (0.0019)
0.033 (0.0010)
0.032 (0.0027)
0.835 (0.0042)
0.106 (0.0030)
0.027 (0.0018)
?
C B 
?
C C 
?
C D 
?
C E
0.03
0.80
0.14
0.03
0.030 (0.0004)
0.805 (0.0010)
0.133 (0.0009)
0.032 (0.0003)
0.031 (0.0017)
0.800 (0.0035)
0.137 (0.0030)
0.032 (0.0012)
0.031 (0.0033)
0.796 (0.0064)
0.140 (0.0048)
0.033 (0.0030)
?
DC 
?
DD 
?
DE
0.03
0.75
0.22
0.031 (0.0008)
0.752 (0.0017)
0.217 (0.0015)
0.031 (0.0026)
0.756 (0.0053)
0.213 (0.0047)
0.031 (0.0057)
0.766 (0.0085)
0.203 (0.0074)
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Table 27. Parameter estimates with MNAR2 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
State-dep. 
Prob.
p
A1
p
A2
0.90
0.10
0.904 (0.0018)
0.096 (0.0018)
0.904 (0.0019)
0.096 (0.0019)
0.905 (0.0024)
0.095 (0.0024)
p
B1 
p
B2 
p
B3
0.10
0.80
0.10
0.104 (0.0021)
0.805 (0.0026)
0.091 (0.0020)
0.102 (0.0031)
0.809 (0.0034)
0.089 (0.0026)
0.103 (0.0044)
0.815 (0.0050)
0.082 (0.0032)
p
C 2 
p
C 3 
p
C 4
0.10
0.80
0.10
0.097 (0.0019)
0.813 (0.0023)
0.090 (0.0019)
0.084 (0.0033)
0.838 (0.0038)
0.078 (0.0029)
0.073 (0.0047)
0.854 (0.0054)
0.073 (0.0046)
p
D3
p
D4
0.10
0.90
0.101 (0.0023)
0.899 (0.0023)
0.099 (0.0049)
0.901 (0.0049)
0.090 (0.0072)
0.910 (0.0072)
Simulation Results: Scheme 3
Table 28. The average computation time (seconds)
Missing 
Mechanism
30 Day 90 Day 180 Day
MAR 9359 2682 1560
MNAR1 8631 3574 2125
MNAR2 9864 2703 1592
 
Table 29. Parameter estimates with MAR missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Initial 
Prob.
?
A
?
B
?
C
?
D
0.80
0.10
0.07
0.03
0.799 (0.006)
0.102 (0.006)
0.069 (0.004)
0.030 (0.002)
0.794 (0.006)
0.108 (0.005)
0.068 (0.004)
0.030 (0.002)
0.773 (0.007)
0.128 (0.006)
0.068 (0.004)
0.031 (0.002)
Table 30. Parameter estimates with MAR missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Transition 
Prob.
?
AA 
?
AB 
?
AE
0.90
0.07
0.03
0.895 (0.0003)
0.071 (0.0003)
0.031 (0.0002)
0.895 (0.0011)
0.073 (0.0009)
0.032 (0.0005)
0.895 (0.0022)
0.075 (0.0018)
0.030 (0.0010)
?
BA 
?
BB 
?
BC 
?
BE
0.03
0.85
0.09
0.03
0.030 (0.0004)
0.840 (0.0007)
0.093 (0.0005)
0.037 (0.0003)
0.030 (0.0014)
0.835 (0.0022)
0.101 (0.0016)
0.029 (0.0010)
0.029 (0.0029)
0.833 (0.0044)
0.109 (0.0031)
0.029 (0.0019)
?
C B 
?
C C 
?
C D 
?
C E
0.03
0.80
0.14
0.03
0.029 (0.0005)
0.799 (0.0010)
0.140 (0.0009)
0.032 (0.0004)
0.027 (0.0018)
0.793 (0.0039)
0.145 (0.0031)
0.034 (0.0013)
0.026 (0.0030)
0.795 (0.0066)
0.144 (0.0054)
0.035 (0.0031)
?
DC 
?
DD 
?
DE
0.03
0.75
0.22
0.029 (0.0007)
0.758 (0.0017)
0.213 (0.0016)
0.029 (0.0023)
0.762 (0.0047)
0.209 (0.0040)
0.026 (0.0048)
0.773 (0.0090)
0.201 (0.0080)
Table 31. Parameter estimates with MAR missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
State-dep. 
Prob.
p
A1
p
A2
0.90
0.10
0.906 (0.0019)
0.094 (0.0019)
0.914 (0.0019)
0.086 (0.0019)
0.925 (0.0025)
0.075 (0.0025)
p
B1 
p
B2 
p
B3
0.10
0.80
0.10
0.104 (0.0023)
0.830 (0.0026)
0.066 (0.0018)
0.112 (0.0032)
0.849 (0.0036)
0.039 (0.0022)
0.126 (0.0047)
0.847 (0.0048)
0.027 (0.0023)
p
C 2 
p
C 3 
p
C 4
0.10
0.80
0.10
0.139 (0.0024)
0.800 (0.0028)
0.061 (0.0018)
0.191 (0.0048)
0.766 (0.0046)
0.043 (0.0024)
0.203 (0.0069)
0.755 (0.0073)
0.042 (0.0040)
p
D3
p
D4
0.10
0.90
0.149 (0.0029)
0.851 (0.0029)
0.172 (0.0054)
0.828 (0.0054)
0.160 (0.0115)
0.840 (0.0115)
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Table 32. Parameter estimates with MNAR1 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Initial Prob.
?
A
?
B
?
C
?
D
0.80
0.10
0.07
0.03
0.788 (0.007)
0.109 (0.005)
0.073 (0.003)
0.030 (0.003)
0.778 (0.007)
0.120 (0.006)
0.071 (0.004)
0.031 (0.002)
0.754 (0.007)
0.143 (0.006)
0.071 (0.004)
0.032 (0.003)
Table 33. Parameter estimates with MNAR1 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Transition 
Prob.
?
AA 
?
AB 
?
AE
0.90
0.07
0.03
0.891 (0.0004)
0.075 (0.0004)
0.034 (0.0002)
0.892 (0.0012)
0.076 (0.0010)
0.032 (0.0005)
0.894 (0.0019)
0.077 (0.0018)
0.029 (0.0011)
?
BA 
?
BB 
?
BC 
?
BE
0.03
0.85
0.09
0.03
0.031 (0.0004)
0.841 (0.0007)
0.092 (0.0005)
0.036 (0.0003)
0.031 (0.0013)
0.838 (0.0022)
0.097 (0.0015)
0.034 (0.0010)
0.031 (0.0025)
0.838 (0.0039)
0.102 (0.0030)
0.029 (0.0018)
?
C B 
?
C C 
?
C D 
?
C E
0.03
0.80
0.14
0.03
0.031 (0.0005)
0.802 (0.0010)
0.136 (0.0009)
0.031 (0.0003)
0.030 (0.0017)
0.799 (0.0030)
0.138 (0.0026)
0.033 (0.0013)
0.030 (0.0035)
0.797 (0.0061)
0.140 (0.0051)
0.033 (0.0032)
?
DC 
?
DD 
?
DE
0.03
0.75
0.22
0.031 (0.0007)
0.755 (0.0015)
0.214 (0.0014)
0.031 (0.0023)
0.756 (0.0049)
0.213 (0.0040)
0.030 (0.0050)
0.768 (0.0085)
0.202 (0.0076)
Table 34. Parameter estimates with MNAR1 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
State-dep. 
Prob.
p
A1
p
A2
0.90
0.10
0.905 (0.0017)
0.095 (0.0017)
0.905 (0.0021)
0.095 (0.0021)
0.906 (0.0025)
0.094 (0.0025)
p
B1 
p
B2 
p
B3
0.10
0.80
0.10
0.104 (0.0020)
0.807 (0.0026)
0.089 (0.0019)
0.101 (0.0030)
0.814 (0.0037)
0.085 (0.0026)
0.098 (0.0042)
0.823 (0.0042)
0.078 (0.0033)
p
C 2 
p
C 3 
p
C 4
0.10
0.80
0.10
0.099 (0.0019)
0.814 (0.0022)
0.087 (0.0018)
0.085 (0.0030)
0.840 (0.0035)
0.075 (0.0029)
0.075 (0.0043)
0.856 (0.0054)
0.069 (0.0042)
p
D3
p
D4
0.10
0.90
0.105 (0.0027)
0.895 (0.0027)
0.103 (0.0043)
0.897 (0.0043)
0.095 (0.0087)
0.905 (0.0087)
Table 35. Parameter estimates with MNAR2 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Initial Prob.
?
A
?
B
?
C
?
D
0.80
0.10
0.07
0.03
0.791 (0.006)
0.106 (0.005)
0.073 (0.003)
0.030 (0.002)
0.781 (0.007)
0.115 (0.006)
0.072 (0.004)
0.032 (0.003)
0.757 (0.006)
0.139 (0.005)
0.071 (0.004)
0.033 (0.003)
Table 36. Parameter estimates with MNAR2 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
Transition 
Prob.
?
AA 
?
AB 
?
AE
0.90
0.07
0.03
0.892 (0.0004)
0.074 (0.0003)
0.030 (0.0002)
0.892 (0.0010)
0.076 (0.0009)
0.032 (0.0005)
0.895 (0.0021)
0.076 (0.0020)
0.029 (0.0011)
?
BA 
?
BB 
?
BC 
?
BE
0.03
0.85
0.09
0.03
0.032 (0.0004)
0.837 (0.0007)
0.096 (0.0005)
0.035 (0.0003)
0.032 (0.0012)
0.835 (0.0024)
0.100 (0.0017)
0.033 (0.0008)
0.032 (0.0027)
0.835 (0.0044)
0.105 (0.0032)
0.028 (0.0016)
?
CB ?CC ?CD 
?
C E
0.03
0.80
0.14
0.03
0.030 (0.0005)
0.805 (0.0011)
0.134 (0.0010)
0.031 (0.0004)
0.031 (0.0015)
0.799 (0.0029)
0.137 (0.0026)
0.032 (0.0012)
0.031 (0.0038)
0.796 (0.0063)
0.140 (0.0053)
0.033 (0.0025)
?
DC 
?
DD 
?
DE
0.03
0.75
0.22
0.030 (0.0007)
0.752 (0.0016)
0.218 (0.0013)
0.030 (0.0026)
0.756 (0.0047)
0.214 (0.0045)
0.031 (0.0054)
0.766 (0.0093)
0.203 (0.0077)
Table 37. Parameter estimates with MNAR2 missing 
mechanism
True value ?ˆ(ESD) ?ˆ(ESD) ?ˆ(ESD)
30 Days 90 Days 180 Days
State-dep. 
Prob.
p
A1
p
A2
0.90
0.10
0.904 (0.0017)
0.096 (0.0017)
0.904 (0.0018)
0.096 (0.0018)
0.906 (0.0025)
0.094 (0.0025)
p
B1 
p
B2 
p
B3
0.10
0.80
0.10
0.104 (0.0026)
0.805 (0.0027)
0.091 (0.0019)
0.101 (0.0033)
0.810 (0.0039)
0.088 (0.0029)
0.102 (0.0042)
0.816 (0.0045)
0.082 (0.0035)
p
C 2 
p
C 3 
p
C 4
0.10
0.80
0.10
0.097 (0.0021)
0.813 (0.0025)
0.090 (0.0020)
0.083 (0.0028)
0.838 (0.0039)
0.079 (0.0030)
0.073 (0.0052)
0.854 (0.0061)
0.073 (0.0048)
p
D3
p
D4
0.10
0.90
0.101 (0.0023)
0.899 (0.0023)
0.099 (0.0051)
0.901 (0.0051)
0.090 (0.0082)
0.910 (0.0082)
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